While the foundational patient protections enshrined within the No Surprises Act (NSA) are effectively shielding consumers from unexpected medical bills, new, comprehensive research from the Elevance Health Public Policy Institute indicates that the law’s independent dispute resolution (IDR) process is yielding unintended and concerning financial outcomes for a significant segment of planned medical procedures. This unexpected divergence from the legislation’s original intent threatens to inflate healthcare costs across the system, ultimately burdening employers and American families through higher premiums and out-of-pocket expenses.
The Genesis of the No Surprises Act: A Response to a Systemic Problem
The No Surprises Act, signed into law as part of the Consolidated Appropriations Act, 2021, and taking full effect on January 1, 2022, was a landmark piece of bipartisan legislation designed to address a pervasive and frustrating issue: surprise medical billing. For years, patients undergoing emergency procedures or receiving care at in-network facilities often found themselves blindsided by exorbitant bills from out-of-network providers—such as anesthesiologists, assistant surgeons, or radiologists—who had participated in their care without their explicit consent or knowledge of their out-of-network status. These "balance bills" could amount to thousands, even tens of thousands, of dollars, leaving patients in financial distress and often with little recourse.
Prior to the NSA, an estimated 1 in 5 emergency visits and 1 in 6 in-network hospitalizations involved at least one out-of-network bill, leading to significant financial hardship for millions of Americans. The average surprise bill for an emergency room visit, for instance, could range from $600 to over $2,000, depending on the service and location. Congress’s clear intent with the NSA was to remove patients from the middle of these billing disputes, shifting the financial negotiation entirely to providers and insurers. The law broadly prohibits balance billing for emergency services, certain non-emergency services provided by out-of-network providers at in-network facilities, and out-of-network air ambulance services. Central to this new framework was the establishment of the Independent Dispute Resolution (IDR) process, a federal arbitration mechanism intended to resolve payment disagreements between health plans and providers without involving the patient.
Implementation and Early Challenges: A Rocky Start for IDR
The rollout of the No Surprises Act and its IDR process was not without its complexities and controversies. From its inception, the implementation of the IDR mechanism faced legal challenges. Initial interim final rules issued by the Departments of Health and Human Services (HHS), Labor, and the Treasury in 2021 were met with lawsuits from provider groups, who argued that the rules unfairly favored insurers by placing undue emphasis on the "qualifying payment amount" (QPA) – essentially the median contracted rate for a service in a geographic area – during arbitration. Provider organizations contended that this approach did not adequately consider other statutory factors, such as the provider’s experience, quality of outcomes, or the complexity of the service, potentially leading to lower reimbursements and threatening network adequacy.
Multiple federal courts sided with providers, vacating portions of the initial rules and prompting federal agencies to revise their guidance. This back-and-forth created a period of uncertainty and administrative hurdles for both payers and providers, contributing to delays in IDR processing and an initial backlog of cases. Despite these early challenges, the core patient protections of the NSA remained intact and widely praised. However, the sheer volume of IDR disputes quickly began to far outstrip initial governmental projections. The Congressional Budget Office (CBO) originally estimated around 20,000 IDR cases per year, but by late 2022 and throughout 2023, the actual number of disputes submitted surged into the hundreds of thousands, creating a massive administrative burden and raising early alarms about the process’s scalability and potential for unintended consequences. As of late 2023, over 1 million IDR cases had been initiated, a stark contrast to initial forecasts, leading to significant backlogs and processing delays that continue to impact the system.
Elevance Health’s Scrutiny: Unpacking the Study’s Alarming Findings
It is against this backdrop of surging IDR volume that the Elevance Health Public Policy Institute conducted its pivotal research. The study meticulously analyzed more than 7,300 payment disputes specifically involving procedures and services that are typically scheduled in advance. These included common but often complex interventions such as spine surgery, various forms of plastic surgery (e.g., reconstructive procedures), colonoscopies, and other elective or planned medical services. The crucial commonality among these cases was that while the procedures were performed at in-network facilities, the specific providers involved were, for various reasons, out-of-network. This scenario is precisely what the NSA aimed to address for patients, but the study uncovered a worrying trend within the IDR resolution process itself.
The findings were stark and largely favored providers:
- Overwhelming Provider Success: Researchers found that providers prevailed in nearly 90% of the disputed claim lines examined. This high success rate indicates a consistent pattern where arbitrators are frequently ruling in favor of the provider’s requested payment.
- Exorbitant Awarded Payments: Perhaps the most alarming finding was the magnitude of the payments awarded through the federal IDR process. These awarded amounts were frequently tens, and in some cases, even hundreds of times higher than typical in-network commercial rates for the same services. They also vastly exceeded Medicare payment rates, which often serve as a benchmark for reasonable healthcare costs. For example, a procedure for which the typical in-network commercial rate might be $1,000 and Medicare pays $700, could see an IDR award of $10,000 or even $70,000. This dramatic disparity suggests that the IDR process, at least for these planned procedures, is not consistently yielding payments aligned with prevailing market rates or cost-effective benchmarks.
- Concentration of Disputes: The study also revealed that a relatively small number of providers were responsible for a disproportionately large share of the disputes for these planned services, suggesting a systematic approach to leveraging the IDR process.
- Impact on QPA: While the QPA was intended to be a guiding factor, the study implied that other factors considered by arbitrators in these specific cases were often leading to awards significantly above the QPA, diluting its intended cost-containment effect.
- Specific Service Lines: The analysis showed that certain specialty services, particularly those involving high-cost surgical interventions, were frequent subjects of these high-award IDR outcomes.
Catherine Gaffigan, president of health solutions at Elevance Health, articulated the core concern, stating, "The No Surprises Act was designed to protect patients from unexpected medical bills, not to increase healthcare costs. Our Public Policy Institute’s research raises serious concerns that the dispute resolution process is being used for certain scheduled services in ways that diverge from the law’s original intent." She further emphasized the ripple effect: "When the system is exploited, the result is higher costs for employers and families who ultimately bear the burden through higher premiums and health care expenses. Preserving patient protections requires ensuring that the dispute resolution process is used appropriately and functions as Congress intended.” Aliza Gordon, director of research at the institute and co-author of the study, echoed these sentiments, adding, "These findings raise important questions about how the process is functioning and suggest that additional safeguards are needed to help keep healthcare costs affordable." She urged policymakers to consider changes to the law to ensure the IDR process remains focused on its original purpose while continuing to protect patients.
Reactions from Stakeholders: A Divided Landscape
The Elevance Health study immediately ignited reactions across the healthcare ecosystem, highlighting the entrenched divisions between payers and providers, and drawing concern from those footing the bill.
- Payer Organizations (including Elevance Health): Unsurprisingly, health insurance plans and payer organizations largely aligned with Elevance Health’s findings. They contend that the current IDR process, particularly for planned services, is being manipulated by some providers to secure payments far exceeding market rates. They argue that this inflates healthcare costs, leading directly to higher premiums for employers and individuals. Payers advocate for reforms that would re-emphasize the QPA as the primary determinant in IDR decisions, believing this would bring awarded amounts closer to negotiated in-network rates and curb perceived abuses. They might point to the "employer demand changes" article as evidence of broad consensus on this issue.
- Provider Groups: While acknowledging the NSA’s patient protections, provider organizations have historically championed a robust IDR process that considers multiple factors beyond just the QPA. They might counter the Elevance study by arguing that the high success rate and larger awards reflect the true value of their specialized services, the administrative burden of participating in IDR, and the inadequacy of some payers’ initial offers. They might also argue that the QPA is often artificially low, particularly in areas with limited competition or for highly specialized care, and that relying solely on it would jeopardize the financial viability of certain practices, potentially reducing access to care. They would likely emphasize that providers, too, face significant administrative costs and delays in receiving payments through the IDR process.
- Employer Coalitions: Employer groups, who collectively bear a substantial portion of the nation’s healthcare costs through employee benefits, have expressed growing alarm. They directly experience the impact of rising healthcare expenditures through increasing health insurance premiums. The prospect of an IDR process that inflates costs for planned procedures—which are often covered through employer-sponsored plans—is particularly concerning. Organizations like the ERISA Industry Committee (ERIC) and others have previously called for reforms to the IDR process, advocating for greater transparency and a stronger focus on the QPA to ensure affordability.
- Consumer Advocates: While unequivocally supporting the patient protections of the NSA, consumer advocates are likely to express mixed feelings. They would applaud the law’s success in shielding patients from direct surprise bills but would share concerns about the indirect impact of inflated costs on overall healthcare affordability. They would emphasize that while patients are no longer directly billed, they ultimately bear the cost through higher premiums, deductibles, and co-pays. Their focus would be on finding a solution that preserves patient protection without compromising affordability.
- Policymakers and Regulators (HHS/CMS): Federal agencies and congressional committees responsible for overseeing the NSA would likely acknowledge the concerns raised by the Elevance study. They would face pressure to review the IDR process, potentially considering legislative or regulatory amendments. This could involve revisiting the weighting of factors considered by arbitrators, streamlining the process to reduce backlogs, or implementing stronger guardrails to prevent systematic exploitation. However, any proposed changes would likely face intense lobbying from both provider and payer groups, making a consensus difficult to achieve.
The Broader Economic Ripple: Impact on Premiums and System Sustainability
The implications of the Elevance Health study extend far beyond the direct parties involved in IDR disputes. The findings point to a potential systemic flaw that could have significant economic repercussions for the entire U.S. healthcare system.
- Premium Inflation: If providers consistently win disputes at rates "tens to hundreds of times higher" than typical in-network rates, these higher payouts must be absorbed somewhere. Health plans will inevitably pass these increased costs onto employers and individual policyholders through higher premiums. In an environment already grappling with healthcare cost inflation, this additional pressure could make health insurance less affordable for businesses and families, potentially leading to reduced coverage or increased underinsurance.
- Sustainability of the NSA: The IDR process was intended as a "limited payment-dispute backstop." Its current volume and the high cost of awards for planned procedures suggest it is operating far beyond this initial scope. The administrative burden and financial strain on both payers and the federal government to manage hundreds of thousands of disputes annually are enormous. If left unaddressed, the current trajectory could undermine the long-term sustainability and effectiveness of the NSA itself, potentially eroding the very patient protections it was designed to deliver.
- Market Distortions and Network Adequacy: If out-of-network providers can consistently secure significantly higher payments through IDR than they would through direct contract negotiations, it could create perverse incentives. Some providers might be less inclined to join health plan networks, opting instead to remain out-of-network and rely on the IDR process for higher reimbursement. This could destabilize health plan networks, make it harder for patients to find in-network care, and ultimately drive up overall healthcare costs as a greater proportion of services are paid at inflated IDR rates.
- Impact on Value-Based Care: The focus on high, arbitrary IDR awards could also detract from the broader movement towards value-based care, which aims to reward providers for quality outcomes and cost-efficiency. If the IDR process prioritizes high payments over value, it could inadvertently disincentivize efforts to control costs and improve care coordination.
Charting a Path Forward: Calls for Policy Review
The Elevance Health study serves as a critical call to action for policymakers to re-evaluate the functioning of the No Surprises Act’s IDR process. Maintaining the integrity of patient protections while ensuring cost-effectiveness requires a delicate balance and potential adjustments.
Potential policy considerations include:
- Revisiting IDR Guidelines: Policymakers could amend the IDR regulations to provide clearer guidance to arbitrators, perhaps re-emphasizing the QPA as the primary benchmark or establishing clearer guardrails for how other statutory factors are weighed to prevent excessively high awards for routine planned procedures.
- Limiting IDR Scope for Planned Services: Consideration could be given to whether planned, non-emergency services performed by out-of-network providers at in-network facilities should be subject to the same IDR process as emergency or truly unforeseen out-of-network care. Perhaps a different, more streamlined negotiation process could be implemented for these specific scenarios.
- Transparency and Data Collection: Increased transparency regarding IDR outcomes, including anonymized data on awards relative to QPA and typical in-network rates, could provide valuable insights for future policy refinements and help stakeholders understand the process better.
- Streamlining and Efficiency: Addressing the administrative backlog and improving the efficiency of the IDR process itself is crucial. This could involve increasing the number of certified arbitrators, simplifying dispute submission requirements, or implementing technology solutions to expedite case resolution.
- Addressing Repeat Offenders: If, as the study implies, a small number of providers are systematically leveraging the IDR for planned services, policymakers might consider mechanisms to address such patterns, perhaps through enhanced oversight or specific limitations.
The No Surprises Act stands as a testament to the power of legislative action in protecting consumers from predatory billing practices. However, the findings from the Elevance Health Public Policy Institute highlight that even well-intentioned legislation can have unforeseen consequences in its implementation. The challenge now lies in refining the IDR process to ensure it continues to shield patients from financial surprises without inadvertently becoming a conduit for unsustainable healthcare cost inflation, thereby preserving the delicate balance between access, protection, and affordability for all Americans.
